BASi Launches Innovative Glucose Monitoring Project With Pinnacle Technology
BASi Launches Innovative Glucose Monitoring Project With Pinnacle Technology
New Option for High Quality Data Collection for Diabetes Research
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- BASi (Bioanalytical Systems, Inc.) (Nasdaq: BASI) announced today that it is collaborating with Pinnacle Technology Inc. in proof-of-concept studies combining BASi's Culex® NxT automated blood sampling system with Pinnacle's glucose sensor to create an innovative new option for high quality data collection for diabetes and other glucose research.
"The development of new treatments for diabetes is the focus of intense effort by pharmaceutical companies around the world. Most studies rely on external monitors to measure glucose levels in test subjects. As a result, researchers must handle the subjects to obtain blood samples, which causes stress that can alter glucose readings.
"Our approach has two important advantages over this traditional method: automation of blood sampling made possible by our Culex NxT, and accurate monitoring of glucose levels using the Pinnacle glucose sensor with no net removal of blood from the test subjects. This allows researchers to take many glucose readings with no ill effects on the test subjects, resulting in more accurate glucose readings than are possible with manual sampling.
"In addition, the system enables researchers to conduct pharmacokinetic, metabolism, telemetry or microdialysis studies from one set of test subjects instead of using three or four sets, thus lowering study costs.
"Pinnacle Technology's glucose sensor was initially built to monitor neurological glucose levels and adapted to work within the Culex system. BASi's engineering team developed a new tubing set with a built-in sensor interface for the Culex NxT, allowing the placement of the sensor into the blood stream without any stress to the test subjects. Many leading diabetes research teams have shown great interest in our glucose monitoring system, and we will work with them to publish the data we are gathering in our proof-of-concept studies," said Jacqueline M. Lemke, President & CEO and CFO of BASi.
For further information, please contact Brad Gien, BASi Discovery Services Scientist PK/PD at 765-497-8491.
About Pinnacle Technology
Pinnacle Technology Inc., based in Lawrence, Kansas, specializes in researching, designing, and manufacturing turn-key solutions for pre-clinical Central Nervous System data acquisition and analysis. By forging collaborative relationships with clients, Pinnacle is able to develop sophisticated new tools that improve and simplify research. Visit www.pinnaclet.com for more about Pinnacle Technology.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
BASi (Bioanalytical Systems, Inc.)
Jacqueline Lemke, 765-497-5829
President, CEO and CFO
jlemke@BASinc.com
or
Agency Contact:
Berkman Associates
Neil Berkman, 310-477-3118
info@berkmanassociates.com
KEYWORDS: United States North America Indiana Kansas
INDUSTRY KEYWORDS:
The article BASi Launches Innovative Glucose Monitoring Project With Pinnacle Technology originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
